Loading...
XNAS
SILO
Market cap1mUSD
Jun 16, Last price  
0.58USD
1D
-1.21%
1Q
-57.95%
IPO
-97.72%
Name

Silo Pharma Inc

Chart & Performance

D1W1MN
P/E
—
P/S
25.42
EPS
—
Div Yield, %
—
Shrs. gr., 5y
50.96%
Rev. gr., 5y
12.19%
Revenues
72k
0.00%
00105,522-107,114-145,185-669,480847,407040,56940,92371,26472,10272,10272,102
Net income
-4m
L+18.70%
-49,803-39,44632,911-376,549-409,498-1,112,974356,536-969,463-1,048,086-3,129,8653,903,741-3,908,551-3,700,683-4,392,880
CFO
-4m
L+18.90%
-46,303-21,473-181,609-1,062,960-1,016,756-143,555-284,618272,637-794,324-1,156,996-2,278,016-3,497,622-3,224,498-3,833,914
Earnings
Aug 11, 2025

Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
URL
https://silopharma.com/
IPO date
Jan 05, 2012
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
72
0.00%
72
0.00%
72
1.18%
Cost of revenue
2,672
3,928
2,450
Unusual Expense (Income)
NOPBT
(2,600)
(3,856)
(2,378)
NOPBT Margin
Operating Taxes
1
Tax Rate
NOPAT
(2,600)
(3,856)
(2,379)
Net income
(4,393)
18.70%
(3,701)
-5.32%
(3,909)
-200.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,242
(471)
4,941
BB yield
-98.96%
10.62%
-64.38%
Debt
Debt current
(364)
Long-term debt
Deferred revenue
722
794
866
Other long-term liabilities
Net debt
(7,081)
(7,665)
(11,734)
Cash flow
Cash from operating activities
(3,834)
(3,224)
(3,498)
CAPEX
Cash from investing activities
974
(4,147)
87
Cash from financing activities
3,242
(471)
4,941
FCF
(2,600)
(3,856)
(2,379)
Balance
Cash
7,081
7,665
11,370
Long term investments
Excess cash
7,077
7,662
11,367
Stockholders' equity
(15,262)
(10,878)
(7,171)
Invested Capital
21,018
17,848
18,013
ROIC
ROCE
EV
Common stock shares outstanding
3,680
3,080
2,284
Price
0.89
-38.19%
1.44
-57.14%
3.36
-52.84%
Market cap
3,276
-26.14%
4,435
-42.22%
7,675
-43.85%
EV
(3,805)
(3,230)
(4,059)
EBITDA
(2,594)
(3,766)
(2,378)
EV/EBITDA
1.47
0.86
1.71
Interest
5
5
2
Interest/NOPBT